Physician
Internal Medicine
Dr. Filip Janku, MD
|
|
Give Review
Filip Janku is an expert in the field of Internal Medicine. Filip Janku is a published MD as well. He has 95 publications published. The latest was: Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel deLivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
- Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.
- Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
- P1.09Phase I clinical study of intratumoral injection of Clostridium novyi-NT spores in patients with advanced Cancer.
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung Cancer.
- MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.
- Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
- Olanzapine for cachexia in patients with advanced Cancer: an exploratory study of effects on weight and metabolic cytokines.
- Targeted therapy for genetic Cancer syndromes: Fanconi anemia, medullary thyroid Cancer, tuberous sclerosis, and RASopathies.
- Targeted therapy for genetic Cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome.
- Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic Disorders.
- Targeted therapy for hereditary Cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome.
- Targeted therapy for hereditary Cancer syndromes: hereditary breast and ovarian Cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
- Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.
- Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid Tumors.
- Deciding site of biopsy at metastatic relapse: reply.
- Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab.
- Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
- Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.
- A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced Cancer.
- Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I clinic.
- Triple Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents.
- Outcomes of patients with advanced Cancer and KRAS mutations in phase I clinical trials.
- Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of...
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses.
- Characteristics and survival of patients with advanced Cancer and p53 mutations.
- BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
- Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.
- Anastrozole and everolimus in advanced gynecologic and Breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
- Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
- Outcomes of patients with metastatic cervical Cancer in a phase I clinical trials program.
- Unique molecular signatures as a hallmark of patients with metastatic breast Cancer: Implications for current treatment paradigms.
- Erdheim-Chester Disease: Characteristics and Management.
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia.
- MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory Cancers: an open-label, phase 1 dose-escalation and expansion study.
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal Cancers in a phase I unit.
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced Cancers.
- Tumor heterogeneity in the clinic: is it a real problem?
- Phase I clinical trial of bendamustine and bevacizumab for patients with advanced Cancer.
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors.
- Molecular targets for Cancer therapy in the PI3K/AKT/mTOR pathway.
- A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
- Barriers to Study Enrollment in Patients With Advanced Cancer Referred to a Phase I Clinical Trials Unit.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma.
- Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced Cancer.
- A pilot study of temsirolimus and body composition.
- P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy.
- Bringing target-matched PI3King from the bench to the clinic.
- Bevacizumab-based treatment in colorectal Cancer with a NRAS Q61K mutation.
- Non-Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment.
- A tale of two histiocytic Disorders.
- Biomarker-Directed Therapy of Squamous Carcinomas of the Head and Neck: Targeting PI3K/PTEN/mTOR Pathway.
- PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
- Personalized medicine in a phase I clinical trials program: the MD anderson Cancer center initiative.
- Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009.
- Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced Tumors: implications for therapy.
- KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors.
- A framework for genomic biomarker actionability and its use in clinical decision making.
- Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal Cancer.
- Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
- Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives.
- FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors.
- Retreatment after Secondary Resistance or Mixed Response: A Pilot Study.
- Molecular detection of disseminated breast Cancer cells in the bone marrow of early breast Cancer patients using quantitative RT PCR for CEA.
- [Meningeal carcinomatosis as the first manifestation of gastric adenocarcinoma].
- Mammaglobin A, a novel marker of minimal residual disease in early stages breast Cancer.
- [Minimal residual disease in Breast carcinoma].
- Highlights from the 7th central European lung Cancer conference.
- A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast Cancer.
- KIT receptor is expressed in more than 50% of early-stage Malignant melanoma: a retrospective study of 261 patients.
- Symptomatic control of hypoglycaemia with prednisone in refractory metastatic Pancreatic insulinoma.
- 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast Cancer: single institution prospective study.
- Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung Cancer: a randomized study.
- BRAF mutations in advanced Cancers: clinical characteristics and outcomes.
- A Phase I Trial of Liposomal Doxorubicin, Bevacizumab and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies.
- Novel therapeutic targets in non-small cell lung Cancer.
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers.
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center.
- Autophagy as a target for antiCancer therapy.
- Outcomes of patients with advanced non-small cell lung Cancer treated in a phase I clinic.
- PIK3CA mutations in patients with advanced Cancers treated with PI3K/AKT/mTOR axis inhibitors.
- Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement.
- Response of histiocytoses to imatinib mesylate: fire to ashes.
- Targeted therapy in non-small-cell lung Cancer--is it becoming a reality?
- Patients with advanced head and neck Cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
- Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).
- Adjuvant interferon in high-risk Melanoma: end of the era?
- Personalized medicine in advanced non-small-cell lung Cancer: reality or wishful thinking?
- Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory Cancers.
- Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.
- Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel deLivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
- Aetna
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- GEHA
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tricare
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1740584507 | |
| NPPES Provider LastName | JANKU | |
| NPPES Provider FirstName | FILIP | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 439.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 3.42 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740584507 |
| Last Name Of The Provider | JANKU |
| First Name Of The Provider | FILIP |
| View All |
Similar Doctors
|
|
Dr. Herbert L. Fred, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jennifer B. Cowart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ricardo E. Nuila, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claudine D. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonas J. Gunawan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bashar Hannawi, MD |
|
|
Dr. Chi Si Choi, MD |
|
|
Dr. Frank V. Fossella, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason Westin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward S. Kim, MD |
|
|
Dr. Michael J. Fisch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rammurti T. Kamble, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vahid Afsharkharghan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravindra Kumar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melina Awar, MD
This Doctor is OpenDoctor Recommended.
|